IGI Submits IND Application for Multispecific Cancer Candidate ISB 2301

manufacturing-news
Image Courtesy: Pixabay

Ichnos Glenmark Innovation, Inc (IGI), a clinical-stage biotechnology company developing multispecific therapies for cancer, has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for ISB 2301. The investigational candidate is being developed for the treatment of solid tumours.

ISB 2301 is a first-in-class pentaspecific immune cell activator designed to recognise three tumour-associated antigens and engage two types of immune cells: T cells and natural killer (NK) cells. The molecule combines five binding specificities within a single candidate, bringing together tumour recognition and immune-cell activation.

The approach is intended to address the biological differences found within solid tumours and the mechanisms these tumours use to suppress immune responses. By targeting multiple tumour-associated antigens while activating both T cells and NK cells, ISB 2301 is being developed to support a broader anti-tumour response.

The candidate was developed using IGI’s proprietary BEAT® Multispecific Platform. Its design incorporates several mechanisms of action, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition and the induction of a sustained type 1 immune response.

Lida Pacaud, MD, President and Chief Executive Officer of IGI, said the IND submission marks an important step in moving the company’s multispecific oncology pipeline into clinical development. She said ISB 2301 brings together multiple tumour-targeting and immune-engaging functions in one molecule. Based on the preclinical findings, IGI plans to begin a Phase 1 clinical trial involving patients with solid tumours in 2027.

In preclinical studies, ISB 2301 demonstrated favourable pharmacokinetic and tolerability profiles in non-human primates. The planned clinical evaluation will examine the candidate’s safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumour activity in patients with advanced solid tumours.

The IND submission adds to IGI’s pipeline of investigational multispecific cancer treatments. The company is also developing ISB 2001, a CD38 × BCMA × CD3 trispecific T-cell engager for patients with relapsed or refractory multiple myeloma. The candidate has shown anti-tumour activity and a favourable safety profile in an investigational Phase 1 study involving heavily pretreated patients.

Ichnos Glenmark Innovation is a fully integrated, clinical-stage biotechnology company headquartered in New York, focused on developing biologic treatments for cancer. Its pipeline includes multispecific therapies developed using its proprietary BEAT® technology platform. The company is working to develop treatments for both blood cancers and solid tumours, with the aim of improving outcomes for patients.